Pharmachemie Cisplatin ANDA Should Get 180-Day Exclusivity As First To File
Executive Summary
Generic exclusivity should be granted to the first paragraph IV ANDA holder to file, regardless of subsequent changes to the application's certification or to the patent challenged, Pharmachemie B.V. asserted in a June 9 citizen's petition maintaining its right to 180 days of exclusivity for generic cisplatin.
You may also be interested in...
Florida Pedigree Enforcement For 30 “Specified” Drugs Begins Sept. 1
Pfizer's cholesterol-lowering drug Lipitor could be one of the first additions to a list of 30 drugs with new "pedigree" paper requirements in Florida
Medicare Rx Should Cover Dual-Eligibles, Merck Says; Industry Applauds Bill
Merck wants dual-eligible seniors to be covered by the new Medicare Rx benefit to ensure that they are protected by formulary practice standards included in the bill
Florida Pedigree Enforcement For 30 “Specified” Drugs Begins Sept. 1
Pfizer's cholesterol-lowering drug Lipitor could be one of the first additions to a list of 30 drugs with new "pedigree" paper requirements in Florida